The purpose of the study is to evaluate how well Atogepant works in treating a single migraine attack. Participants will be randomly assigned to receive either Atogepant or a placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the initial phase. This helps ensure that the results are not influenced by expectations about the treatment. After this phase, there will be an “open-label extension,” where all participants will have the opportunity to receive Atogepant.

Throughout the study, participants will take the medication when they experience a migraine attack and will be monitored for their response to the treatment. The study will assess various outcomes, such as the relief of headache pain and the ability to return to normal activities. The trial aims to provide valuable information about the safety and effectiveness of Atogepant for people who suffer from migraines.

The purpose of the study is to evaluate how safe and well-tolerated rimegepant is when used for the acute treatment of migraines in young people. Participants in the study will take the medication over a period of time, and researchers will monitor them for any side effects or adverse reactions. The study is open-label, meaning that both the participants and the researchers know which treatment is being administered.

Throughout the study, participants will be regularly assessed to ensure their safety and to gather information on any side effects they may experience. The study aims to provide valuable insights into the use of rimegepant for managing migraines in children and adolescents, helping to determine its suitability as a treatment option for this age group.

The purpose of the study is to evaluate how well rimegepant works in treating acute migraine attacks, which can occur with or without aura. Aura refers to visual or sensory disturbances that some people experience before a migraine headache. Participants in the study will receive either rimegepant or a placebo and will be monitored to see if they experience pain relief and freedom from other bothersome symptoms like nausea, sensitivity to light (photophobia), and sensitivity to sound (phonophobia) within two hours of taking the medication.

The study will take place over a period of time, during which participants will be asked to report their symptoms and any changes they experience. The goal is to determine if rimegepant can help reduce the severity and duration of migraine attacks in young people, allowing them to return to their normal activities more quickly. The study will also assess whether participants need additional medication to manage their symptoms after taking the study medication.

Participants in the study will be randomly assigned to receive either Atogepant, Topiramate, or a placebo. A placebo is a substance with no active medication, used to compare the effects of the actual drugs. The study will last for several weeks, during which participants will take the assigned medication and report any side effects or changes in their migraine symptoms. The study aims to find out if Atogepant is as effective and safe as Topiramate, which is already used for migraine prevention.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their migraine patterns. The study will also include an open-label extension, where all participants may have the opportunity to receive Atogepant to further assess its long-term safety and effectiveness. This trial is an important step in understanding how these medications can help people who suffer from migraines and improve their quality of life.

The purpose of this study is to evaluate the long-term safety and tolerability of Atogepant when used over a period of 156 weeks. Participants will take a 60 mg dose of Atogepant once daily. The study is designed to observe how well participants tolerate the medication over this extended period and to monitor any side effects that may arise. This is an open-label study, meaning that both the researchers and participants know which treatment is being administered.

Throughout the study, participants will be regularly monitored for any adverse events, which are any unwanted effects that occur during the trial. The study will also assess any significant changes in laboratory test results, heart function as measured by electrocardiograms (ECGs), and vital signs such as blood pressure and heart rate. The goal is to ensure that Atogepant is safe for long-term use in preventing migraines in those who suffer from this condition.

The purpose of the study is to assess how well Atogepant works in reducing the number of migraine days each month over a 12-week period. Participants will be randomly assigned to receive either Atogepant or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the trial.

Throughout the study, participants will take the medication daily and will be monitored for any changes in their migraine symptoms and overall health. The study will also track any side effects that may occur. By the end of the 12-week period, researchers hope to gather valuable information on the potential benefits and safety of Atogepant for young people with episodic migraine.

Participants in the study will take Atogepant in the form of a tablet, which is taken orally. The study will monitor participants for any side effects or adverse events, which are unexpected medical problems that occur during treatment. This includes regular checks on their health through laboratory tests, heart monitoring using an Electrocardiogram (ECG), and assessments of vital signs like blood pressure and heart rate. The study will also look at any changes in mood or behavior, especially any thoughts of self-harm, using a tool called the Columbia-Suicide Severity Rating Scale.

The study is designed to last for a significant period, allowing researchers to gather comprehensive data on the long-term effects of Atogepant. Participants will be closely monitored throughout the study to ensure their safety and well-being. This research aims to provide valuable insights into the use of Atogepant for preventing migraines in children and teenagers, potentially offering a new option for managing this challenging condition.

The study will test whether taking amiloride tablets can reduce the frequency of migraine attacks with aura. The medication will be taken orally each day for three months, with a maximum daily dose of 10 mg. The total amount of medication received during the entire study period will not exceed 900 mg.

The research aims to understand if blocking specific brain channels with amiloride can help prevent the occurrence of migraine aura symptoms. During the study, participants will need to track their migraine episodes and any changes in their condition. The study will also monitor how the treatment affects daily activities and overall well-being.